Christine Fandozzi

1.7k total citations
21 papers, 579 citations indexed

About

Christine Fandozzi is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Christine Fandozzi has authored 21 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 12 papers in Infectious Diseases and 4 papers in Epidemiology. Recurrent topics in Christine Fandozzi's work include Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (3 papers). Christine Fandozzi is often cited by papers focused on Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (3 papers). Christine Fandozzi collaborates with scholars based in United States, Canada and France. Christine Fandozzi's co-authors include Joseph P. Vacca, John A. McCauley, David B. Olsen, Donald J. Graham, Nigel J. Liverton, Steven W. Ludmerer, Rhonda A. Torres, Jeffrey P. Jones, Kenneth R. Korzekwa and Daniel R. McMasters and has published in prestigious journals such as Journal of the American Chemical Society, Gastroenterology and Journal of Medicinal Chemistry.

In The Last Decade

Christine Fandozzi

21 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine Fandozzi United States	11	296	195	194	166	106	21	579
Ian Stansfield United Kingdom	15	256 0.9×	195 1.0×	177 0.9×	272 1.6×	203 1.9×	23	745
John K. Pratt United States	15	186 0.6×	103 0.5×	134 0.7×	207 1.2×	311 2.9×	23	711
Anja Sandström Sweden	17	153 0.5×	56 0.3×	118 0.6×	296 1.8×	351 3.3×	52	756
Kuo-Chi Cheng United States	14	96 0.3×	39 0.2×	77 0.4×	128 0.8×	147 1.4×	22	440
Alessandro Deplano Italy	16	270 0.9×	223 1.1×	20 0.1×	203 1.2×	192 1.8×	31	709
Bheemarao G. Ugarkar United States	16	43 0.1×	127 0.7×	236 1.2×	378 2.3×	311 2.9×	24	791
Xiaojiao Li China	15	100 0.3×	147 0.8×	53 0.3×	138 0.8×	222 2.1×	65	696
Harry B. Marr United States	10	56 0.2×	84 0.4×	118 0.6×	201 1.2×	79 0.7×	13	554
Mark Orlowski United States	8	139 0.5×	81 0.4×	89 0.5×	81 0.5×	78 0.7×	12	340
Joseph F. Leone United States	11	56 0.2×	48 0.2×	101 0.5×	149 0.9×	90 0.8×	16	324

Countries citing papers authored by Christine Fandozzi

Since Specialization

Citations

This map shows the geographic impact of Christine Fandozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Fandozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Fandozzi more than expected).

Fields of papers citing papers by Christine Fandozzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Fandozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Fandozzi. The network helps show where Christine Fandozzi may publish in the future.

Co-authorship network of co-authors of Christine Fandozzi

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Fandozzi. A scholar is included among the top collaborators of Christine Fandozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Fandozzi. Christine Fandozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chu, Xiaoyan, Grace Chan, Robert Houle, et al.. (2022). In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. The AAPS Journal. 24(3). 45–45. 8 indexed citations

Caro, Luzelena, Thomayant Prueksaritanont, Christine Fandozzi, et al.. (2021). Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults. Clinical Drug Investigation. 41(2). 133–147. 5 indexed citations

Caro, Luzelena, Larissa Wenning, Hwa-ping Feng, et al.. (2019). Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. European Journal of Clinical Pharmacology. 75(5). 665–675. 10 indexed citations

Feng, Hwa-ping, Zifang Guo, Christine Fandozzi, et al.. (2019). Pharmacokinetic Interactions Between the Fixed‐Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants. Clinical Pharmacology in Drug Development. 8(7). 952–961. 3 indexed citations

Feng, Hwa-ping, Zifang Guo, Luzelena Caro, et al.. (2019). Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate. Clinical Pharmacology in Drug Development. 8(7). 962–970. 1 indexed citations

Feng, Hwa-ping, Luzelena Caro, Christine Fandozzi, et al.. (2018). Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. The Journal of Clinical Pharmacology. 58(5). 666–673. 14 indexed citations

Feng, Hwa-ping, Zifang Guo, Lisa Ross, et al.. (2018). Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. Journal of Antimicrobial Chemotherapy. 74(3). 710–717. 4 indexed citations

Marshall, William L., Larissa Wenning, Xiaobi Huang, et al.. (2017). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 43(3). 321–329. 4 indexed citations

Caro, Luzelena, Larissa Wenning, Zifang Guo, et al.. (2017). Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 61(12). 9 indexed citations

10.

Garner, Rachel M., Shobha Gopalakrishnan, John A. McCauley, et al.. (2015). Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selectiveN‐methyl‐D‐aspartate receptor antagonist. Pharmacology Research & Perspectives. 3(6). e00198–e00198. 37 indexed citations

11.

Manns, Michael P., John M. Vierling, Bruce R. Bacon, et al.. (2014). The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology. 147(2). 366–376.e6. 28 indexed citations

12.

Coburn, Craig A., Peter T. Meinke, Wei Chang, et al.. (2013). Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity. ChemMedChem. 8(12). 1930–1940. 143 indexed citations

13.

Bell, Ian M., Craig A. Stump, Steven N. Gallicchio, et al.. (2012). MK-8825: A potent and selective CGRP receptor antagonist with good oral activity in rats. Bioorganic & Medicinal Chemistry Letters. 22(12). 3941–3945. 19 indexed citations

14.

Raheem, Izzat T., Michael J. Breslin, Christine Fandozzi, et al.. (2012). Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 22(18). 5903–5908. 25 indexed citations

15.

Melamed, Jeffrey Y., Nathan R. Kett, Anthony L. Gotter, et al.. (2010). Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(15). 4700–4703. 21 indexed citations

16.

Carroll, Steve S., John A. McCauley, Paul J. Coleman, et al.. (2010). MK-5172, a Novel Macrocyclic Inhibitor of NS3/4a Protease Demonstrates Efficacy Against Viral Resistance in the Chimpanzee Model of Chronic Hepatitis C Virus Infection. Antiviral Research. 86(1). A21–A21. 1 indexed citations

17.

Graham, Donald J., L K Handt, Christine Fandozzi, et al.. (2008). Evaluation of MK-7009, A Novel Macrocyclic Inhibitor of NS3/4A Protease, in the Chimpanzee Model of Chronic Hepatitis C Virus Infection. Antiviral Research. 78(2). A23–A23. 2 indexed citations

18.

Liverton, Nigel J., M. Katharine Holloway, John A. McCauley, et al.. (2008). Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease. Journal of the American Chemical Society. 130(14). 4607–4609. 77 indexed citations

19.

Olsen, David B., Steve S. Carroll, L K Handt, et al.. (2007). [791] HCV ANTIVIRAL ACTIVITY AND RESISTANCE ANALYSIS IN CHRONICALLY INFECTED CHIMPANZEES TREATED WITH NS3/4A PROTEASE AND NS5B POLYMERASE INHIBITORS. Journal of Hepatology. 46. S298–S298. 12 indexed citations

20.

Torres, Rhonda A., Kenneth R. Korzekwa, Daniel R. McMasters, Christine Fandozzi, & Jeffrey P. Jones. (2007). Use of Density Functional Calculations To Predict the Regioselectivity of Drugs and Molecules Metabolized by Aldehyde Oxidase. Journal of Medicinal Chemistry. 50(19). 4642–4647. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact